Immunos Therapeutics Raises $74 Million Series B Financing Round
06/07/22, 1:30 AM
Money raised
$74 million
Round Type
series b
- New investors Samsara, Lightspeed, Gimv, and Mission BioCapital further strengthen investor base and expand transatlantic footprint
Company Info
Additional Info
ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases. ImmunOs’ lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses.